No connection

Search Results

RNAC vs SMTI

RNAC
Cartesian Therapeutics, Inc.
BEARISH
Price
$7.04
Market Cap
$186.6M
Sector
Healthcare
AI Confidence
95%
SMTI
Sanara MedTech Inc.
BEARISH
Price
$20.77
Market Cap
$190.4M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
RNAC
--
SMTI
--
Forward P/E
RNAC
-4.17
SMTI
40.73
P/B Ratio
RNAC
-1.45
SMTI
31.28
P/S Ratio
RNAC
66.72
SMTI
1.85
EV/EBITDA
RNAC
-0.89
SMTI
18.8

Profitability

Gross Margin
RNAC
0.0%
SMTI
92.71%
Operating Margin
RNAC
-2316.68%
SMTI
10.5%
Profit Margin
RNAC
0.0%
SMTI
-36.43%
ROE
RNAC
--
SMTI
-1.75%
ROA
RNAC
-14.82%
SMTI
7.1%

Growth

Revenue Growth
RNAC
--
SMTI
4.7%
Earnings Growth
RNAC
--
SMTI
--

Financial Health

Debt/Equity
RNAC
--
SMTI
8.13
Current Ratio
RNAC
8.65
SMTI
1.8
Quick Ratio
RNAC
8.45
SMTI
1.53

Dividends

Dividend Yield
RNAC
--
SMTI
--
Payout Ratio
RNAC
0.0%
SMTI
0.0%

AI Verdict

RNAC BEARISH

RNAC exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in nearly all fundamental health categories. The company suffers from negative equity (Price/Book of -1.45) and an unsustainable operating margin of -2316.68%. While analysts maintain a 'strong_buy' rating with a target of $35.57, this is completely decoupled from the current financial reality of massive earnings misses and negative EPS growth. The combination of insider selling by the CEO and CFO and a 5-year price collapse of 93.8% suggests a high-risk speculative profile.

Strengths
Strong short-term liquidity with a Current Ratio of 8.65
High analyst conviction (Strong Buy consensus)
Recent short-term price momentum (1-week gain of 17.7%)
Risks
Negative shareholder equity (P/B -1.45)
Extreme valuation relative to sales (P/S 66.72)
Severe operational inefficiency (Operating Margin -2316.68%)
SMTI BEARISH

SMTI exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 8.13. While the company maintains an impressive gross margin of 92.71%, this is offset by consistent net losses and a track record of massive earnings misses (average surprise of -587.40% over the last 4 quarters). There is a stark disconnect between the 'Strong Buy' analyst consensus and the underlying deterministic health metrics, which suggest high insolvency risk. The stock's long-term price trajectory is sharply negative, despite a recent short-term bounce.

Strengths
Exceptional Gross Margin (92.71%) indicating strong product pricing power
Positive Operating Margin (10.50%) suggesting core business viability
Adequate short-term liquidity with a Current Ratio of 1.80
Risks
Extreme leverage with a Debt/Equity ratio of 8.13
Critical financial health indicated by Piotroski F-Score of 2/9
Chronic inability to meet earnings estimates with severe negative surprises

Compare Another Pair

RNAC vs SMTI: Head-to-Head Comparison

This page compares Cartesian Therapeutics, Inc. (RNAC) and Sanara MedTech Inc. (SMTI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile